The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Growth In Market Size Of The Radiopharmaceutical Theranostics Market During 2026–2030?
The radiopharmaceutical theranostics market has experienced rapid growth in recent years. It is projected to expand from $3.27 billion in 2025 to $3.76 billion in 2026, driven by a compound annual growth rate (CAGR) of 15.0%. Historically, this growth has been influenced by factors such as the expansion of nuclear medicine applications, increasing cancer incidence rates, advancements in radioisotope production techniques, the growth in diagnostic imaging integration, and the early adoption of theranostic treatment models.
The radiopharmaceutical theranostics market is poised for significant expansion in the upcoming years. Its valuation is projected to achieve $6.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.3%. This projected growth can be attributed to several factors, including increased investments in precision oncology, a rising demand for personalized radiopharmaceutical therapies, the broadening of clinical trials for novel isotopes, enhanced collaboration between diagnostics and therapeutics, and continuous innovation in isotope supply chains. Foremost trends expected in this period involve the intensified development of targeted theranostic radiopharmaceuticals, the expanding utilization of PET-based personalized therapies, a greater adoption of alpha and beta emitters in oncology, the growth of cyclotron-based isotope production, and a heightened emphasis on precision oncology applications.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11951&type=smp
What Major Growth Factors Are Impacting The Radiopharmaceutical Theranostics Market?
The increasing prevalence of cancer is anticipated to stimulate the expansion of the radiopharmaceutical theranostics market in the future. Cancer is characterized as a condition involving the intricate and atypical multiplication of cells, capable of invading and spreading throughout the body. Radiopharmaceutical theranostics aids in managing cancer by offering precise and customized methodologies. For example, in 2023, the American Cancer Society, a US-based voluntary cancer health organization, projected that approximately 1.9 million new cancer cases would be diagnosed in the US, with around 609,820 fatalities potentially resulting from the disease. Additionally, 88% of those diagnosed are expected to be 50 years of age or older. Consequently, the growing occurrence of cancer is a key factor propelling the growth of the radiopharmaceutical theranostics market.
Which Segment-Based Categories Are Covered In The Radiopharmaceutical Theranostics Market?
The radiopharmaceutical theranostics market covered in this report is segmented –
1) By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers
2) By Source: Nuclear Reactors, Cyclotrons
3) By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, Other Radioscopes
4) By Indication: Oncology, Cardiology, Neurology, Other Indications
5) By End User: Hospitals, Diagnostic Imaging Centers, Academic And Research Institutes, Other End Users
Subsegments:
1) By Alpha Emitters: Actinium-225, Radium-223, Bismuth-213, Other Alpha-Emitting Radiopharmaceuticals
2) By Beta Emitters: Iodine-131, Lutetium-177, Yttrium-90, Other Beta-Emitting Radiopharmaceuticals
3) By Positron Emission Tomography (PET) Tracers: Fluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Other PET Tracers
Which Trends Are Influencing The Expansion Of The Radiopharmaceutical Theranostics Market?
Leading companies within the radiology services market are concentrating on creating innovative products to boost diagnostic precision, enhance workflow effectiveness, and extend service capacities. These product advancements include cloud-based platforms, AI-powered imaging solutions, and integrated radiology operating systems that simplify image handling, reporting, and patient care. For instance, in February 2024, Yellow Cross Pharmaceuticals Private Limited, a US-based telemedicine practice management company, introduced a new consultancy service designed to improve teleradiology management for healthcare providers, spurred by the increasing scarcity of radiologists. This service aids medical groups in managing technology, billing, and marketing, allowing them to efficiently expand remote care options. Yellowcross’s objective is to improve patient access, lower healthcare expenses, and elevate the standard of care through personalized telemedicine solutions.
Who Are The Prominent Players Across The Radiopharmaceutical Theranostics Market?
Major companies operating in the radiopharmaceutical theranostics market are Cardinal Health Inc., GE HealthCare Technologies Inc., Bayer AG, China Grand Pharmaceutical & Healthcare., Lantheus Medical Imaging Inc., Curium Pharma, Advanced Accelerator Applications, Telix Pharmaceuticals Ltd., Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Navidea Biopharmaceuticals Inc., Jubilant DraxImage Inc., NorthStar Medical Radioisotopes LLC, Blue Earth Diagnostics Ltd., Precirix NV, SpectronRx, Viewpoint Molecular Targeting Inc., NuView Life Sciences, Alpha-9 Theranostics Inc., RadioMedix Inc, RayzeBio Inc, Fusion Pharmaceuticals Inc, Actinium Pharmaceuticals Inc., Eckert & Ziegler Strahlen- und Medizintechnik AG, Ariceum Therapeutics GmbH, Radiopharm Theranostics Ltd, Ratio Therapeutics Inc, Primo Biotechnology, Bivision Biomedical Technology (Nanjing) Co. Ltd.
Access The Complete Radiopharmaceutical Theranostics Market Report:
Which Region Stands As The Largest Contributor To The Radiopharmaceutical Theranostics Market?
North America was the largest region in the radiopharmaceutical theranostics market in 2025. The regions covered in the radiopharmaceutical theranostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Radiopharmaceutical Theranostics Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=11951&type=smp
Browse Through More Reports Similar to the Global Radiopharmaceutical Theranostics Market 2026, By The Business Research Company
Radiology As A Service Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiology-as-a-service-global-market-report
Radiology Information Systems Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/radiology-information-systems-global-market-report
Oncologists Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model